Fluvoxamine
Alternative Names: Luvox
Fluvoxamine is an antidepressant (SSRI) that has shown promising early evidence for treating long COVID, particularly fatigue. A 2026 randomized controlled trial in nearly 400 patients found that people taking fluvoxamine had meaningful reductions in fatigue and improved quality of life over 2–3 months, making it the strongest psychiatric medication evidence so far for established long COVID symptoms. These benefits are thought to come from its anti-inflammatory effects and action on the sigma-1 receptor, which may help regulate immune and stress responses.
Treatment Type: Prescription Medication
Treatment Class: SSRI
Treatment Modality: Oral
Review Summary
Based on the provided review, Fluvoxamine shows modest effectiveness for Long COVID fatigue, with a 2026 randomized trial demonstrating improved fatigue and quality of life compared to placebo at the 100 mg twice daily dose, with benefits sustained at 90 days. The treatment is also listed in current guidance as under investigation for brain fog and cognitive symptoms, though specific efficacy data for these symptoms is not detailed in the review.
This summary was generated by users' reviews
Breakdown by Category
Each categories are rated on a 1–5 scale, with 5 being the most favorable outcome and 1 being the least. These scores are averaged across all user reviews to provide a clear sense of how this treatment typically performs in each area.
Explore various treatment options to empower yourself in making a well-informed choice.
Choose treatments from the menu above to see how they compare side by side.
Choose treatments from the menu above to see how they compare side by side.
Choose treatments from the menu above to see how they compare side by side.
4.0
AI Summary of User Experiences
Not medical advice.
Based on the provided review, Fluvoxamine shows modest effectiveness for Long COVID fatigue, with a 2026 randomized trial demonstrating improved fatigue and quality of life compared to placebo at the 100 mg twice daily dose, with benefits sustained at 90 days. The treatment is also listed in current guidance as under investigation for brain fog and cognitive symptoms, though specific efficacy data for these symptoms is not detailed in the review.
Reviews
Filter by reviewer type Pro